Products from BPS Bioscience require a minimum order value above 400€
Application: / Use as target cells in CAR-T or NK co-culture killing assays./ In vitro and in vivo bioluminescence imaging.
Background: CD20 (cluster of differentiation 20), also known as MS4A1, is a glycosylated phosphoprotein expressed on the cell surface of B cells. CD20 is a highly attractive target antigen for immunotherapy because it is highly expressed in more than 90% of patients with B cell lymphoma. First approved in 1997, Rituximab (Rituxan) is a chimeric monoclonal antibody targeting CD20 and has been classified by the World Health Organization as an “Essential Medicine”. Since then, additional monoclonal antibodies against CD20 have been approved or are being tested in clinical trials for the treatment of multiple sclerosis (MS), chronic lymphocytic leukemia (CLL), follicular lymphoma, diffuse large B cell lymphoma (DLBCL), rheumatoid arthritis, non-Hodgkin’s lymphoma, systemic lupus erythematosus (SLE), and myalgic encephalomyelitis (chronic fatigue syndrome). More recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse.
Description: Firefly Luciferase CD20 K562 Cell Line is a K562 cell line constitutively expressing full length human CD20 (cluster of differentiation 20) (also known as MS4A1, Genbank #NM_152866) and firefly luciferase. This cell line has been validated by flow cytometry and luciferase activity.
Genbank: NM_152866
Host Cell Line: K562, human lymphoblast cell line, suspension.
Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage.
Supplied As: Each vial contains ˃1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)
Target: CD20
Uniprot: P11836
Warnings: Avoid freeze/thaw cycles.
Biosafety Level: BSL-1
English
Deutsch
